Home Tags Johnson & Johnson
Tag: Johnson & Johnson
J&J was ordered to pay $572 million for helping fuel the opioid epidemic. The company’s market cap increased $15 billion in response.
Johnson & Johnson's June regulatory filings revealed nearly $15 billion in cash reserves, signaling the company can easily pay the judge's fine.
The CEOs at Disney, Johnson & Johnson, Fidelity, and Wal-mart all started in entry-level positions before climbing the ladder to the top job.
J&J tumbles amid reports the DOJ launched a criminal investigation into whether it lied about its baby powder’s cancer risks
The probe coincides with thousands of civil claims from cancer patients saying J&J's baby powder is responsible for their illnesses.
Johnson & Johnson shares rose in pre-market trading on Tuesday after topping analysts' quarterly earnings expectations.
Regulators just approved the first new depression drug since the 1980s, and some see blockbuster potential
A drug inspired by ketamine just became the first new type of depression drug in 35 years. The FDA approved the nasal spray made by Johnson & Johnson.
Johnson & Johnson is being investigated by the SEC over fears its baby powder may cause cancer — here’s how worried you should be
Baby powder is made with talc, a mineral that can contain asbestos fibers. But the science is far from settled on whether talc contributes to cancer.
Johnson & Johnson was subpoenaed by the Department of Justice and Securities and Exchange Commission over matters relating to its baby powder.
A depression drug that’s been called ‘the most important discovery in half a century’ just got a big step closer to FDA approval
Esketamine, a first-of-its-kind depression drug made by Johnson & Johnson, got a big nod on Tuesday from a group of experts convened by regulators.
Chris Jordan, the exercise physiologist who created the 7-minute workout, explains why it can help get your heart pumping and build muscle.
A fresh crop of promising drugs is poised to change the way depression is treated for the first time in decades. Here are the ones to watch in 2019.
Researchers are on the hunt for better drugs to treat depression, a leading cause of disability worldwide. Promising options include ketamine and psilocybin.